logged in.
news
Latest News
Posted 27-Nov-2015
Carbaglu® (carglumic acid 200mg dispersible tablets) is now a TGA Registered ProductPosted 17-Feb-2015
Emerge Health Appoints DHL Supply Chain PartnerPosted 02-Feb-2015
Emerge Health Partners With Chiesi Farmaceutici For Distribution Rights To Market Curosurf® (poractant alfa) in AustraliaPosted 07-Mar-2014
Emerge Health Supports Hospital Pharmacy at SHPA Conference, Canberra 2012Posted 01-Nov-2012
Posted 28-Nov-2018
Emerge Health Christmas and New Year Trading Hours
To facilitate your order planning during the forthcoming Christmas / New Year holiday period, please find the Emerge Health holiday season operating and ordering hours as listed below. Date Order Processing Timeline Business Hours (AEDT) 17/12/2018 Last Ambient/Cold Chain orders processed for all states..
Posted 17-Oct-2018
OCALIVA obeticholic acid tablets (5 mg and 10 mg) are now TGA Registered Products
On the 21 September 2018, OCALIVA was granted approval by the Therapeutic Good Administration (TGA) as a Schedule 4 Prescription Medicine. OCALIVA is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate respon..
OCALIVA obeticholic acid tablets (5 mg and 10 mg) are now TGA Registered Products Overview
Posted 10-May-2018
Emerge Health Change of Office Address
Emerge Health is relocating to a new office. This will be effective from Monday, 21 May 2018. Our new address will be: Suite 3, 22 Gillman Street, HAWTHORN EAST VIC 3123 Our phone & fax numbers plus email address for orders and product enquiries will remain the same: Phone:+61 3 9077 4486 Fax:+61 3 8672 0792 ..
Posted 19-Feb-2018
Emerge Health signs marketing and distribution agreement with Diurnal
Diurnal Group plc (“Diurnal” or the “Company”) Diurnal signs marketing and distribution agreement for the commercialisation of ALKINDI® and CHRONOCORT® in Australia and New Zealand with Emerge Health Further validation of Diurnal’s products and approach to global marketing and distribution in high value markets outside core Europe and..
Emerge Health signs marketing and distribution agreement with Diurnal Overview
Posted 01-Feb-2018
Media Release: SATIVEX® (nabiximols) now available in Australia for MS spasticity
SATIVEX (nabiximols) is the only prescription cannabinoid medicine licensed by the TGA in Australia for the treatment of moderate and severe spasticity due to multiple sclerosis (MS) Availability of SATIVEX in Australia follows UK, Canada, various European and other countries where SATIVEX is prescribed routinely for this indication ..
Media Release: SATIVEX® (nabiximols) now available in Australia for MS spasticity Overview
Posted 01-Dec-2017
ASACOL® (mesalazine) PBS Listing
EMERGE HEALTH PTY LTD, a specialty medicines company, today announced the PBS listing of ASACOL 800mg mesalazine enteric-coated tablets [AUST R 261420], effective as of the 1st of December 2017. ASACOL is indicated for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults. All hospital pharmacies ..
Posted 02-Dec-2016
Transfer of Sponsorship of CLEVIPREX® from The Medicines Company Australia Pty Ltd
EMERGE HEALTH PTY LTD a specialty medicines company, today announced that it will be taking over the Sponsorship of CLEVIPREX® (clevidipine) effective as of the 6th of December 2016. Following the Transfer of Sponsorship there will be no change to the availability of CLEVIPREX for your hospital or patients. All hospital pharmacies will be ..
Transfer of Sponsorship of CLEVIPREX® from The Medicines Company Australia Pty Ltd Overview
Posted 26-Oct-2016
Daniele De Luca Tour
As part of Emerge Health’s commitment to further education and creating forums to discuss the latest research and topics in respiratory research and neonatal management of RDS (Respiratory Distress Syndrome), the company sponsored Professor Daniele De Luca to Australia as an international speaker. Prof. De Luca is currently the Medical Dir..
Posted 22-Jun-2016
Emerge Health Supports HGSA 40th Annual Scientific Meeting
Emerge Health will be supporting the Human Genetics Society of Australia (HGSA) at the 40th Annual Scientific Meeting in Hobart, Australia from the 6th – 9th August. If you are attending the event, we will be at booth 11 so come over and say hello! The conference promises to be an exciting meeting with strong scientific content, covering v..
Emerge Health Supports HGSA 40th Annual Scientific Meeting Overview
Posted 18-Dec-2015
Emerge Health Christmas Trading Hours
From the 23rd of December 2015 to the 8th of January 2016, Emerge Health will not be operating during the normal business hours of 9:00AM to 5:00PM. If you wish to place an order during this period, please refer to the customer support hours below. 2015 December 23rd 9:00AM - 1:00PM December 24t..
Posted 27-Nov-2015
Emerge Health supports Hospital Pharmacists at SHPA's 41st Conference
Emerge Health will be supporting the Society of Hospital Pharmacists Australia (SHPA) Medicines Management National Conference again this year in Melbourne from the 3rd to 5th of December, as Exhibitors. If you are attending SHPA’s 41st Conference, please come and visit Emerge Health at Stand 39 to speak to us and take advantage of our limi..
Emerge Health supports Hospital Pharmacists at SHPA's 41st Conference Overview
Posted 17-Feb-2015
Carbaglu® (carglumic acid 200mg dispersible tablets) is now a TGA Registered Product
EMERGE HEALTH PTY LTD the exclusive distributor of Carbaglu® (carglumic acid 200mg dispersible tablets) in Australia is pleased to announce approval has been granted by the Therapeutic Good Administration (TGA) for the following indications: Hyperammonaemia due to N-acetylglutamate synthase primary deficiency Hyperammonaemia due to Org..
Carbaglu® (carglumic acid 200mg dispersible tablets) is now a TGA Registered Product Overview
Posted 02-Feb-2015
Emerge Health Appoints DHL Supply Chain Partner
Emerge Health Pty Ltd is pleased to announce that distribution of all products will be managed by Melbourne based DHL Supply Chain (Australia) Pty Ltd. DHL Supply Chain is a market leader in customer focused logistics services for the life science and research communities globally. With the ability to manage distribution of various product ..
Posted 07-Mar-2014
Emerge Health Partners With Chiesi Farmaceutici For Distribution Rights To Market Curosurf® (poractant alfa) in Australia
EMERGE HEALTH PTY LTD a specialty medicines company, today announced it has the exclusive marketing and distribution rights of Curosurf® in Australia. Curosurf® (poractant alfa) is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants and for prophylactic use in infants at risk of RDS About Eme..
Posted 01-Nov-2012
Emerge Health Supports Hospital Pharmacy at SHPA Conference, Canberra 2012
With its ever growing presence as a supplier to Hospital Pharmacy across Australia, Emerge Health will be attending the SHPA Conference in Canberra on Nov 1-3. Sponsoring the Conference as an exhibitor, Emerge Health will also launch two new innovative and exclusive hospital pharmacist tools. These two web enabled tools were developed on the f..
Emerge Health Supports Hospital Pharmacy at SHPA Conference, Canberra 2012 Overview
Posted 01-Feb-2012
New Partnership with Orphan Europe
Emerge Health announces a new partnership with Orphan Europe for exclusive distribution of products in Australia and New Zealand Australia and New Zealand News Emerge Health Pty Ltd (Emerge) is pleased to announce a new partnership with Orphan Europe (a division of the Recordati Group Italy), for the exclusive distribution in Australia..